Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.760
+0.040 (2.33%)
At close: Feb 6, 2026, 4:00 PM EST
1.780
+0.020 (1.14%)
After-hours: Feb 6, 2026, 7:54 PM EST
Milestone Pharmaceuticals Employees
Milestone Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees decreased by 14 or -29.79% compared to the previous year.
Employees
33
Change (1Y)
-14
Growth (1Y)
-29.79%
Revenue / Employee
n/a
Profits / Employee
-$1,757,939
Market Cap
178.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 33 | -14 | -29.79% |
| Dec 31, 2023 | 47 | 8 | 20.51% |
| Dec 31, 2022 | 39 | 10 | 34.48% |
| Dec 31, 2021 | 29 | 1 | 3.57% |
| Dec 31, 2020 | 28 | -2 | -6.67% |
| Sep 30, 2020 | 28 | -2 | -6.67% |
| Jun 30, 2020 | 28 | 5 | 21.74% |
| Mar 31, 2020 | 30 | 10 | 50.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 220 |
| Molecular Partners AG | 153 |
| Prelude Therapeutics | 131 |
| Surrozen | 41 |
| Sol-Gel Technologies | 34 |
| Opus Genetics | 18 |
| Galectin Therapeutics | 15 |
| Sagimet Biosciences | 14 |
MIST News
- 4 days ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewsWire
- 23 days ago - Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense - Seeking Alpha
- 4 weeks ago - Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency - GlobeNewsWire
- 7 weeks ago - Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript - Seeking Alpha
- 2 months ago - Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewsWire
- 3 months ago - Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - GlobeNewsWire
- 3 months ago - Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025 - GlobeNewsWire